You can add location information to your Tweets, such as your city or precise location, from the web and via third-party applications. You always have the option to delete your Tweet location history. Learn more
Vaccine candidate was well tolerated at all doses with no serious adverse events reported within 28 days. Most adverse events were mild or moderate; 83% of those receiving low & middle doses & 75% in the high dose group reporting at least 1 adverse reaction within 7 days (2/3)pic.twitter.com/BxC93Yp5gj
Study of 108 adults finds vaccine produced neutralising antibodies and T-cell response against SARS-CoV-2, but further research is needed to confirm whether the vaccine protects against #SARSCoV2 infection (3/3)pic.twitter.com/Bwh0jZfnYb
"This report of an immunogenic, tolerable vaccine candidate is encouraging at the starting line for #COVID19 vaccine development."
NEW Linked Comment from N Lee & A McGeer on Zhu et al's study of a recombinant Ad5 vectored COVID-19 vaccine https://hubs.ly/H0qXVSW0 pic.twitter.com/wzokP4cD1F
They would already be well on their way with their own challenge trials.
Encouraging news. Thanks for sharing.
Encouraging and promising!
The incidence of fever is concerning though this is probably from the vector.
17% grade 3 adverse-events in high-dose arm (largely fever);
although similar response d.14, 
at d.28 after high-dose
dude, this is THE Lancet.
Thats a great news! Keep working
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
